Zhong Guo Ji Jin Bao·2025-12-10 14:56Core Viewpoint - Xinfeng Pharmaceutical is facing legal challenges as it has been prosecuted for alleged corporate bribery, which may negatively impact its brand reputation and future business development [2][3][5]. Group 1: Legal Issues - On December 10, Xinfeng Pharmaceutical announced that it has received materials for prosecution regarding alleged corporate bribery from the procuratorial organ [2][3]. - The company is currently in the prosecution review stage and will cooperate with relevant authorities while appointing defense lawyers for the case [5]. Group 2: Financial Performance - For the first three quarters of this year, Xinfeng Pharmaceutical reported revenue of 4.266 billion yuan, a year-on-year decrease of 6.55% [8]. - The net profit attributable to shareholders was 152 million yuan, down 13.74% year-on-year, with projections indicating a more than 60% decline in net profit for 2024 [8]. Group 3: Company Background - Xinfeng Pharmaceutical is primarily engaged in pharmaceutical manufacturing, including traditional Chinese medicine cultivation, new drug research and development, production, and sales, focusing on cardiovascular and digestive system products [8]. - The company has faced negative news in recent years, including a bribery case involving its subsidiary, Guizhou Keka Pharmaceutical Co., Ltd., which is 99.99% owned by Xinfeng Pharmaceutical [6].